Ignite Creation Date:
2025-12-24 @ 10:56 PM
Ignite Modification Date:
2026-03-15 @ 12:12 PM
Study NCT ID:
NCT01973569
Status:
COMPLETED
Last Update Posted:
2020-02-12
First Post:
2013-10-25
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment
Sponsor:
Daiichi Sankyo
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
AMG162-D-J301
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None